MORAb 028

Drug Profile

MORAb 028

Alternative Names: MORAb-028; MT 228

Latest Information Update: 13 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Micromet Inc
  • Developer Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 16 Jul 2014 Discontinued - Phase-I for Malignant melanoma (Metastatic disease) in USA (Intratumoural & IV)
  • 07 Jun 2011 Morphotek suspends a phase I trial for Malignant melanoma in USA (NCT01123304)
  • 06 Oct 2010 Phase-I clinical trials in metastatic Malignant melanoma in USA (Intratumoural & IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top